Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$395MCash on Hand
28.5mo Cash Runway
Follow RAPP by emailGet an email when RAPP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RAPP, unsubscribe in one click. Privacy
📣 What RAPP Says Is Next
first quarter of 2027 · RAP-219: “RAP-219 in bipolar mania: End-of-Phase 2 meeting with the FDA expected in first quarter of 2027; initiation of two Phase 3 pivotal trials expected in second half of 2027.”
Company press release, Nov 4, 2026 · SEC filing
fourth quarter of 2026 · RAP-219: “RAP-219 FOS open-label long-term safety extension of Phase 2a trial: Initial data expected in fourth quarter of 2026.”
Company press release, Nov 4, 2026 · SEC filing
second half of 2027 · “The FDA has cleared the Company’s Investigational New Drug (IND) application for RAP-641, an α6β4 nicotinic acetylcholine receptor (nAChR) agonist, and the Company plans to initiate a Phase 1 clinical trial, with preliminary results expected in the second half of 2027.”
Company press release, Nov 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 4, 2026 ·
Earnings Reported Q3 2026 net loss of $40.2 million, up from $26.9 million, with R&D at $34.3 million and $395.0 million in cash at September 30, plus Oct 2026 financings of about $410.7 million net, funding runway through end of 2029. Positive Phase 2 bipolar mania results and Phase 3 plans were highlighted. Form 8-K · SEC filing · Press release
Nov 4, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 30, 2026 ·
Financing Rapport Therapeutics is offering 8,333,334 shares of common stock at $21.00 per share, plus pre-funded warrants for 1,190,476 shares, for gross proceeds of about $200 million. A concurrent private placement and a $150 million convertible notes offering are also planned. Form 424B5 · SEC filing
Oct 30, 2026 ·
Financing Rapport Therapeutics is offering $150,000,000 of 2.25% convertible senior notes due 2032, with an initial conversion price of about $26.7750 per share. Concurrently it is selling 8,333,334 common shares at $21.00 per share, with up to 1,428,571 more under an option. Form 424B5 · SEC filing
Oct 30, 2026 ·
Financing Rapport priced an underwritten offering of 8,333,334 common shares at $21.00 plus pre-funded warrants for 1,190,476 shares, with underwriters exercising a 1,428,571-share option in full. Net proceeds are about $215.7 million, closing Oct 30, 2026. Form 8-K · SEC filing
Oct 27, 2026 ·
Financing Rapport Therapeutics proposes a public offering of its common stock, with the offering size and price left blank in this preliminary filing. A concurrent convertible notes offering is also planned, and a private placement by one investor is expected but not yet agreed. Shares last traded at $25.33 on October 26, 2026. Form 424B5 · SEC filing
Oct 27, 2026 ·
Financing Rapport Therapeutics proposes an offering of convertible senior notes due 2032, with the amount and interest rate left blank in this preliminary filing. It is concurrent with a separate common stock offering and a related private placement by a certain investor. Form 424B5 · SEC filing
Oct 20, 2026 ·
Clinical trial Rapport reported positive Phase 2 topline results for RAP-219 in acute bipolar mania: a 3.1-point placebo-adjusted YMRS improvement at Week 3 (p=0.045), with well-tolerated safety. The company plans an FDA meeting in Q1 2027 and Phase 3 starts in H2 2027. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2027 · Phase 1 · Recruiting · Study Designed to Evaluate the Safety, Tolerability, and PK of RAP-219 Formulated as an Long Acting Injectable. Registry primary completion date, not a results date
Feb 2028 · Phase 2 · Recruiting · A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures Registry primary completion date, not a results date
Jul 2029 · Phase 3 · Recruiting · Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 Registry primary completion date, not a results date
Jul 2029 · Phase 3 · Recruiting · Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
RAPP holds $395M in cash and short-term investments (as of Sep 30, 2026) and burns about $41.5M/quarter from operations,
an estimated runway of 28.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:7 · Low
Cash runway 28 months
ATM program on file since Mar 2026 +15
Shelf registration (S-3ASR, Mar 2026) +10
Company says cash lasts through the end of 2029 -15We believe that our existing cash, cash equivalents, and short-term investments will enable us to fund our operating expenses and capital expenditure requirements through the end of 2029.10-Q, Nov 2026
Share count +24% in a year +7
Raised after last reported balance sheet (Oct 2026) -10
Share count 59,279,630 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full RAPP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RAPP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.